



1617
1617
CC

INFORMATION DISCLOSURE STATEMENT	Application #	09/913,402
	Confirmation #	8312
	Filing Date	August 14, 2001
	First Inventor	NAGAE
	Art Unit	1617
	Examiner	Sharareh, Shahn timer J.
	Docket #	P07336US00/BAS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

S I R :

This IDS is submitted pursuant to 37 CFR. §1.97-1.98 and includes the following:

- ☒ A listing of the references on PTO-1449.
- ☒ A copy of all **non-US** references which are listed on the PTO-1449 (US refs not required).
- ☐ A copy of a corresponding foreign **Search Report** which explains the relevance of the references noted therein.
- ☐ A separate **explanation of relevance**.

Please note the following particulars concerning the filing of this IDS:

- ☐ 1. This IDS is filed at whichever is the latest of:
 - within three months of the filing date of a NATIONAL APPLICATION other than a CPA, or
 - within three months of the date of entry into the NATIONAL STAGE as set forth in 37 CFR. §1.491 in an international application, or
 - before the mailing date of a first Office Action on the merits or after filing of an RCE (*but if a first Office Action is mailed but not yet received and the date on the face of the attached foreign communication makes it evident that this IDS is submitted within three months from the mailing of the search report, then applicant is entitled to have this IDS considered under 2.B. below and such boxes should be considered as having been checked*).
- ☒ 2. This IDS is filed **after a first Office Action**, but before a Final Action, Allowance, or any other action which closes prosecution, **and**:
 - ☒ A. Is accompanied by a payment in the amount of \$180.00 required by 37 CFR. §1.17(p).
- or
- ☐ B. I hereby state that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
- ☐ C. I hereby state that no item of information in this IDS herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR. §1.56(c) more than 3 months prior to the filing of this IDS.
- ☐ D. An appropriate Statement is attached.


08/23/2006 HNGUYEN1 00000064 09913482

01 FC:1806

180.00 OP

- ☐ 3. This IDS is filed **after** a final action or allowance, but on/before payment of the issue fee, and:
- ☐ A. is accompanied by a payment in the amount of \$180.00 required by 37 CFR. §1.17(p).
- and
- ☐ B. I hereby state that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
- ☐ C. I hereby state that no item of information in this IDS herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR. §1.56(c) more than 3 months prior to the filing of this IDS.
- ☐ D. An appropriate Statement is attached.
- ☐ 4. This IDS does not comply with 37 CFR 1.97-1.98, and is being filed **for placement in the file** pursuant to 37 CFR. §1.97(i). .
- ☒ 5. It will also be appreciated that:
- a. It is believed that this IDS complies fully with 37 CFR 1.56 and 1.97-98 and with MPEP § 609; but if for some reason it does not and will not be entered, the examiner is requested to telephone the undersigned so that any deficiency can be timely remedied.
- b. Some of the documents may have markings thereon, but no significance should be attached to those markings.
- c. These documents are not necessarily analogous art.
- d. Where an English language translation of an abstract is provided from a public source, applicant cannot vouch for the accuracy of that translation.
- ☒ 6. If no payment is enclosed and a fee is due in connection with this communication or if the payment enclosed is insufficient, the Director is authorized to charge any fee or additional fee due with this communication to Deposit Account No. 12-0555.

Respectfully submitted,



By: B. Aaron Schulman
Registration No.: 31877

Date: August 22, 2006

STITES & HARBISON PLLC ♦ 1199 North Fairfax St. ♦ Suite 900 ♦ Alexandria, VA 22314
TEL: 703-739-4900 ♦ FAX: 703-739-9577 ♦ CUSTOMER No. 00881



Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 1 of 1

Application # 09/913,402

Information # 8312

Filing Date August 14, 2001

First Inventor NAGAE

Art Unit 1617

Examiner Sharareh, Shahnam J.

Docket # P07336US00/BAS

U.S. PATENT DOCUMENTS

Exam. Initial*	Document No. Number - Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.
	US-			
	US-			

FOREIGN PATENT DOCUMENTS

Exam. Initial*	Country-Number-Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.	Trans- lation

NON PATENT LITERATURE DOCUMENTS

Exam. Initial*	Include NAME of the author (in CAPS), Title of Article/Item, Date, Page(s), Volume-Issue No., Publisher, City and/or Country where published	Trans- lation
	SAITO, T.; HAYASHI, J.; AIZAWA, K.: 'Acute Effects of Photodynamic Treatment on Elastic Fibre Network in Atherosclerotic Plaques of Rabbit Aorta' LASERS IN MEDICAL SCIENCE, vol. 13, 1998, pages 126-131, London.	
	STERNBERG E D ET AL: 'Porphyrin-based Photosensitizers for Use in Photodynamic Therapy' TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, VOL. 54, NO. 17, 23 April 1998 (1998-04-23), pages 4251-4202, ISSN: 0040-4020.	
	LEVY J G: 'Photodynamic therapy' TRENDS IN BIOTECHNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 13, no. 1, January 1995 (1995-01), pages 14-18, ISSN: 0167-7799.	
	'Tin ethyl etiopurpurin significantly inhibits vascular smooth muscle cell proliferation in vivo', 'WILLIAM D. COATS JR. ET AL', 'BIOCHEMISTRY AND CELL BIOLOGY', 74/3/00-00-1996, 325-331.	
	P.C. DARTASCH ET AL.: 'Photodynamic Therapy of vascular Stenosis? Response of Cultured Human Smooth Muscle Cells from Non-Atherosclerotic Arteries and Atheromatous Plaques Following Treatment with Photosensitizing Porphyrins', Proceedings. SPIE - THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING, 1990, vol. 1462, pages 77-80.	
	NAGAE ET AL.: 'Photodynamic therapy with mono-L-aspartyl chlorine e6 against thickening of a vascular intima of blood vessel: Experimental investigations of laser light irradiation on the whole face of a vascular lumen of blood vessel', '62 ANNUAL SCIENTIFIC MEETING OF JAPANESE CIRCULATION SOCIETY', 1998, vol. 62 PAGE 465, ISSN: 0047-1828.	Yes
	JENKINS ET AL.: 'Intra-arterial Photodynamic Therapy Using 5-ALA in a Swine Model', 'EUR. J. VASC. ENDOVASC. SURG', 1998, vol. 16 pages 282-291.	

Examiner Signature

Date Considered

* Examiner: Initial if considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

361LT:5573:35535:1:ALEXANDRIA